Works matching DE "SMALL cell lung cancer"

Results: 4143
    1
    2

    Exomics and immunogenics.

    Published in:
    OncoImmunology, 2014, v. 3, n. 1, p. N.PAG, doi. 10.4161/onci.27817
    By:
    • Champiat, Stéphane;
    • Ferté, Charles;
    • Lebel-Binay, Sophie;
    • Eggermont, Alexander;
    • Soria, Jean Charles
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17

    Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257).

    Published in:
    Journal of Experimental & Clinical Cancer Research (17569966), 2025, v. 44, n. 1, p. 1, doi. 10.1186/s13046-025-03434-3
    By:
    • Pasello, Giulia;
    • Pigato, Giulia;
    • Scattolin, Daniela;
    • Lando, Stefania;
    • Potente, Sara;
    • Romualdi, Chiara;
    • Roma, Anna;
    • Resi, Maria Vittoria;
    • Frega, Stefano;
    • Ferro, Alessandra;
    • Maso, Alessandro Dal;
    • Bonanno, Laura;
    • Guarneri, Valentina;
    • Lazzarini, Elisabetta;
    • Indraccolo, Stefano
    Publication type:
    Article
    18

    Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive‐stage small cell lung cancer (ES‐SCLC): ECOG‐ACRIN EA5161.

    Published in:
    Cancer (0008543X), 2025, v. 131, n. 12, p. 1, doi. 10.1002/cncr.35938
    By:
    • Leal, Ticiana A.;
    • Wang, Yating;
    • Dowlati, Afshin;
    • Chay, Christopher H.;
    • Chen, Yuanbin;
    • Mohindra, Amit R.;
    • Razaq, Mohammad;
    • Ajuja, Harish G.;
    • Liu, Jijun;
    • King, David M.;
    • Sumey, Christopher J.;
    • Ramalingam, Suresh S.
    Publication type:
    Article
    19
    20
    21
    22

    ONECUT2 reprograms neuroendocrine fate and is an actionable therapeutic target in small cell lung cancer.

    Published in:
    Molecular Medicine, 2025, v. 31, n. 1, p. 1, doi. 10.1186/s10020-025-01267-6
    By:
    • Gutiérrez, Mirian;
    • Zamora, Irene;
    • Iriarte, Raquel;
    • Pajares, María José;
    • Yang, Qian;
    • Qian, Chen;
    • Otegui, Nerea;
    • Fernández-Irigoyen, Joaquín;
    • Santamaría, Enrique;
    • Alcala, Nicolas;
    • Sexton-Oates, Alexandra;
    • Fernández-Cuesta, Lynnette;
    • Barajas, Miguel;
    • Calvo, Alfonso;
    • Montuenga, Luis M.;
    • Knudsen, Beatrice;
    • You, Sungyong;
    • Freeman, Michael R.;
    • Encío, Ignacio;
    • Rotinen, Mirja
    Publication type:
    Article
    23
    24

    Lung cancer news.

    Published in:
    Oncolog-Hematolog, 2025, n. 71, p. 3
    By:
    • Grigorescu, Alexandru C.
    Publication type:
    Article
    25
    26
    27
    28
    29
    30
    31

    Small Cell Lung Cancer: A Review.

    Published in:
    JAMA: Journal of the American Medical Association, 2025, v. 333, n. 21, p. 1906, doi. 10.1001/jama.2025.0560
    By:
    • Kim, So Yeon;
    • Park, Henry S.;
    • Chiang, Anne C.
    Publication type:
    Article
    32
    33
    34
    35
    36
    37

    Bayesian-Optimized Convolutional Neural Networks for Classifying Primary Tumor Origin of Brain Metastases from MRI.

    Published in:
    Brain Sciences (2076-3425), 2025, v. 15, n. 5, p. 450, doi. 10.3390/brainsci15050450
    By:
    • Nawabi, Jawed;
    • Eminovic, Semil;
    • Hartenstein, Alexander;
    • Baumgaertner, Georg Lukas;
    • Schnurbusch, Nils;
    • Rudolph, Madhuri;
    • Wasilewski, David;
    • Onken, Julia;
    • Siebert, Eberhard;
    • Wiener, Edzard;
    • Bohner, Georg;
    • Dell'Orco, Andrea;
    • Wattjes, Mike P.;
    • Hamm, Bernd;
    • Fehrenbach, Uli;
    • Penzkofer, Tobias
    Publication type:
    Article
    38
    39

    PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of amivantamab plus lazertinib for non-small cell lung cancer, durvalumab for small cell lung cancer, tislelizumab for esophageal cancer, tisotumab vedotin for cervical cancer, ivosidenib for leukemia, and venetoclax for lymphoma in Japan

    Published in:
    International Journal of Clinical Oncology, 2025, v. 30, n. 6, p. 1049, doi. 10.1007/s10147-025-02758-6
    By:
    • Matsumura, Noriomi;
    • Mandai, Masaki
    Publication type:
    Article
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50